Navigation Links
Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc
Date:5/4/2009

DUBLIN, May 4 /PRNewswire/ -- Circ Pharma Limited ("Circ Pharma") and Elan Corporation plc ("Elan") today announced that they have entered into a Development Agreement to develop a chronotherapeutic formulation of Tramadol for the treatment of moderate to moderately severe pain.

The product incorporates Circ Pharma's proprietary drug delivery technology enabling once daily dosing. Circ's technology provides for minimized delivery to the body during sleeping hours, acceleration of drug absorption immediately prior to the waking hours and the subsequent maintenance of efficacious drug levels for the remainder of the waking hours. Circ has successfully completed Phase I testing on the product.

Currently the worldwide market for pain treatments is worth about US$26 billion and is forecast to grow to about $31 billion by 2011. In the US and Europe the moderate to severe pain market was estimated to be worth about $6.7 billion in 2007. The tramadol market in the US and Europe was worth about $1.1 billion in 2008.

Circ Pharma intends to seek a licensing partner for worldwide commercial distribution of the product.

The agreement with Elan provides that Elan support the continued formulation and manufacturing activities required to seek regulatory approval for this product in the United States and elsewhere. "Elan's extensive experience, know-how and technology for the development and manufacture of scheduled products for the US market will ensure that we can quickly and efficiently complete all the development and clinical activities required for Chrono Tramadol" said Circ Pharma's Chief Technical Officer, Margot Foynes.

About Circ Pharma

Circ Pharma is a specialty pharmaceutical product development company whose mission is to develop differentiated novel formulations of products based on existing drugs that provide incremental patient benefit. Circ Pharma has a strong intellectual property portfolio and technology in the areas of targeted and chronotherapeutic drug delivery and a broad clinical stage pipeline of novel product opportunities in a number of indications including cardiovascular and pain indications. http://www.circpharma.com

    Further Information:

    Media Contact
    Mr. Ray Gordon, Gordon MRM
    Telephone: +353-1-6650450
    E-mail: ray@gordonmrm.ie



'/>"/>
SOURCE Circ Pharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics
2. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
3. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
4. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
5. Idenix Pharmaceuticals Reports First Quarter Financial Results
6. Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. Vanda Pharmaceuticals Reports First Quarter 2009 Results
11. Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... They call it the “hairy ball.” ... depiction of a system of linkages and connections so complex and dense that ... computer science at Worcester Polytechnic Institute (WPI) and director of the university’s bioinformatics ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... with the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s ... hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical ...
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading provider ... nationwide oncology Clinical Nurse Educator (CNE) network, which will launch ... for communication among health care professionals to enhance the patient ... office staff, and other health care professionals to help women ... cancer. ...
Breaking Biology Technology:
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
(Date:3/24/2017)... DUBLIN , Mar 24, 2017 Research ... Vehicle Access System Market Analysis & Trends - Industry Forecast to ... ... poised to grow at a CAGR of around 15.1% over the ... This industry report analyzes the market estimates and forecasts for ...
Breaking Biology News(10 mins):